Home LiteratureArticle Details
PMID: 15247485 Published · ppublish English Journal Article Review

Neurobiology of alpha-synuclein.

Molecular neurobiology ·Vol. 30 ·No. 1 ·2004-08-00 ·Pages 1-21

Vekrellis K, Rideout HJ, Stefanis L

Abstract

Alpha-synuclein is an abundant neuronal protein that has been linked both to normal synaptic function and to neurodegeneration. Most significantly, mutations in the gene encoding for alpha-synuclein are responsible for Parkinson's disease (PD) in rare familial cases, and the aggregated protein is a major component of Lewy bodies found in sporadic PD. Here we review recent data regarding the structure, the regulation at the transcriptional and posttranslational level, and the physiologic and aberrant functions of alpha-synuclein. We focus in particular on the fibrilization potential of alpha-synuclein and on its link with defects in protein degradation.

MeSH Terms
Animals Humans Nerve Tissue Proteins/biosynthesis,chemistry,genetics,physiology Nervous System Diseases/genetics,metabolism Synucleins alpha-Synuclein
Chemicals
Nerve Tissue Proteins SNCA protein, human Synucleins alpha-Synuclein
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Vekrellis Kostas
Neurobiology Laboratory, Institute of Biomedical Research of the Academy of Athens, Greece, Columbia University, New York, NY.
Rideout Hardy J
Stefanis Leonidas
References (172)
172 references, click to expand
  1. alpha-Synuclein shares physical and functional homology with 14-3-3 proteins.
    J Neurosci. 1999 Jul 15;19(14):5782-91 PMID: 10407019
  2. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.
    Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11282-6 PMID: 8248242
  3. Nuclear localization of alpha-synuclein and its interaction with histones.
    Biochemistry. 2003 Jul 22;42(28):8465-71 PMID: 12859192
  4. Identification of two distinct synucleins from human brain.
    FEBS Lett. 1994 May 23;345(1):27-32 PMID: 8194594
  5. Accelerated alpha-synuclein fibrillation in crowded milieu.
    FEBS Lett. 2002 Mar 27;515(1-3):99-103 PMID: 11943202
  6. Failure of the ubiquitin-proteasome system in Parkinson's disease.
    Nat Rev Neurosci. 2001 Aug;2(8):589-94 PMID: 11484002
  7. Synuclein expression is decreased in rat substantia nigra following induction of apoptosis by intrastriatal 6-hydroxydopamine.
    Neurosci Lett. 1999 Nov 12;275(2):105-8 PMID: 10568510
  8. Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system.
    Hum Mol Genet. 2001 Dec 15;10(26):3101-9 PMID: 11751692
  9. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein.
    J Biol Chem. 2002 Jan 18;277(3):1641-4 PMID: 11707429
  10. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch.
    Neuron. 1995 Aug;15(2):361-72 PMID: 7646890
  11. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
    J Neurobiol. 2002 Oct;53(1):1-10 PMID: 12360578
  12. Alpha-synuclein expression in substantia nigra and cortex in Parkinson's disease.
    Mov Disord. 1999 May;14(3):417-22 PMID: 10348463
  13. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.
    Science. 2001 Nov 9;294(5545):1346-9 PMID: 11701929
  14. Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    J Neurochem. 2001 Jan;76(2):637-40 PMID: 11208927
  15. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine.
    Neurosci Lett. 2002 Mar 8;320(3):146-50 PMID: 11852183
  16. Structural organization of alpha-synuclein fibrils studied by site-directed spin labeling.
    J Biol Chem. 2003 Sep 26;278(39):37530-5 PMID: 12815044
  17. Alpha-synuclein expression localizes to the Golgi apparatus in bovine adrenal medullary chromaffin cells.
    Brain Res. 2003 Sep 12;984(1-2):233-6 PMID: 12932858
  18. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis.
    FASEB J. 2001 Apr;15(6):916-26 PMID: 11292651
  19. Rat alpha-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex.
    J Neurochem. 2000 Nov;75(5):2221-4 PMID: 11032911
  20. The rat brain synucleins; family of proteins transiently associated with neuronal membrane.
    Brain Res Mol Brain Res. 1991 Oct;11(3-4):335-43 PMID: 1661825
  21. Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form.
    J Biol Chem. 2002 Jan 4;277(1):671-8 PMID: 11679584
  22. Chaperone-like activity of synucleins.
    FEBS Lett. 2000 May 26;474(1):116-9 PMID: 10828462
  23. Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture.
    Brain Res. 2002 Feb 1;926(1-2):42-50 PMID: 11814405
  24. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.
    Nat Med. 2002 Jun;8(6):600-6 PMID: 12042811
  25. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter.
    Neurobiol Dis. 2001 Jun;8(3):535-9 PMID: 11442360
  26. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein.
    J Neurochem. 2003 Jul;86(1):165-72 PMID: 12807436
  27. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.
    J Neurosci. 2000 Aug 15;20(16):6048-54 PMID: 10934254
  28. Haploinsufficiency at the alpha-synuclein gene underlies phenotypic severity in familial Parkinson's disease.
    Brain. 2003 Jan;126(Pt 1):32-42 PMID: 12477695
  29. Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications.
    J Biol Chem. 2003 Jul 18;278(29):27230-40 PMID: 12857790
  30. Activation of Pyk2/RAFTK induces tyrosine phosphorylation of alpha-synuclein via Src-family kinases.
    FEBS Lett. 2002 Jun 19;521(1-3):190-4 PMID: 12096713
  31. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease.
    Brain Res. 2001 Sep 28;914(1-2):48-56 PMID: 11578596
  32. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system.
    Neuron. 2000 Jan;25(1):239-52 PMID: 10707987
  33. alpha-Synuclein affects the MAPK pathway and accelerates cell death.
    J Biol Chem. 2001 Nov 30;276(48):45320-9 PMID: 11560921
  34. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease.
    Trends Neurosci. 1998 Jun;21(6):249-54 PMID: 9641537
  35. Evidence that the precursor protein of non-A beta component of Alzheimer's disease amyloid (NACP) has an extended structure primarily composed of random-coil.
    Mol Cells. 1997 Feb 28;7(1):78-83 PMID: 9085269
  36. Effects of L-dopa and other amino acids against paraquat-induced nigrostriatal degeneration.
    J Neurochem. 2003 Apr;85(1):82-6 PMID: 12641729
  37. The synucleins.
    Genome Biol. 2002;3(1):REVIEWS3002 PMID: 11806835
  38. Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells.
    Brain Res. 2000 Jun 2;866(1-2):33-43 PMID: 10825478
  39. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal.
    J Neurosci. 1988 Aug;8(8):2804-15 PMID: 3411354
  40. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.
    Nat Genet. 1998 Feb;18(2):106-8 PMID: 9462735
  41. Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores.
    Neurosci Lett. 1999 May 14;266(3):213-6 PMID: 10465711
  42. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions.
    J Biol Chem. 2002 Dec 13;277(50):49071-6 PMID: 12377775
  43. Chronic systemic pesticide exposure reproduces features of Parkinson's disease.
    Nat Neurosci. 2000 Dec;3(12):1301-6 PMID: 11100151
  44. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein.
    J Biol Chem. 2000 Jan 7;275(1):390-7 PMID: 10617630
  45. Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells.
    J Biol Chem. 2002 Dec 13;277(50):48976-83 PMID: 12351642
  46. Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies.
    Am J Pathol. 2003 Jul;163(1):91-100 PMID: 12819014
  47. Immunohistochemical comparison of alpha- and beta-synuclein in adult rat central nervous system.
    Brain Res. 2002 Jun 21;941(1-2):118-26 PMID: 12031554
  48. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
    Exp Neurol. 2002 May;175(1):35-48 PMID: 12009758
  49. The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease?
    Chem Biol. 1995 Mar;2(3):163-9 PMID: 9383418
  50. alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356.
    J Biol Chem. 1999 Sep 3;274(36):25481-9 PMID: 10464279
  51. Proteasomal function is impaired in substantia nigra in Parkinson's disease.
    Neurosci Lett. 2001 Jan 19;297(3):191-4 PMID: 11137760
  52. A role for alpha-synuclein in the regulation of dopamine biosynthesis.
    J Neurosci. 2002 Apr 15;22(8):3090-9 PMID: 11943812
  53. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions.
    Nat Genet. 1999 May;22(1):110-4 PMID: 10319874
  54. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.
    Science. 2002 Feb 1;295(5556):865-8 PMID: 11823645
  55. Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury.
    J Neurochem. 1999 Dec;73(6):2586-99 PMID: 10582622
  56. Clinical phenotype in patients with alpha-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease.
    J Neurol Neurosurg Psychiatry. 2001 May;70(5):662-5 PMID: 11309462
  57. A measure of striatal function predicts motor stereotypy.
    Nat Neurosci. 2000 Apr;3(4):377-83 PMID: 10725928
  58. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.
    Am J Pathol. 1998 Apr;152(4):879-84 PMID: 9546347
  59. beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor.
    Neuron. 2001 Oct 25;32(2):213-23 PMID: 11683992
  60. Alpha-synuclein in Lewy body disease and Alzheimer's disease.
    Brain Pathol. 1999 Oct;9(4):707-20 PMID: 10517509
  61. Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway.
    FASEB J. 2002 Nov;16(13):1826-8 PMID: 12223445
  62. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis.
    Hum Mol Genet. 2001 Apr 15;10(9):919-26 PMID: 11309365
  63. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease.
    FEBS Lett. 2001 Jul 6;500(3):105-8 PMID: 11445065
  64. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.
    Science. 2000 Feb 18;287(5456):1265-9 PMID: 10678833
  65. Why are "natively unfolded" proteins unstructured under physiologic conditions?
    Proteins. 2000 Nov 15;41(3):415-27 PMID: 11025552
  66. alpha-Synuclein gene haplotypes are associated with Parkinson's disease.
    Hum Mol Genet. 2001 Aug 15;10(17):1847-51 PMID: 11532993
  67. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease.
    Neurosci Lett. 2002 Jul 5;326(3):155-8 PMID: 12095645
  68. Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis.
    J Biol Chem. 2000 Nov 3;275(44):34393-8 PMID: 10952980
  69. Genetics of Parkinson's disease.
    Science. 1997 Nov 14;278(5341):1212-3 PMID: 9411743
  70. Release, storage and uptake of catecholamines by a clonal cell line of nerve growth factor (NGF) responsive pheo-chromocytoma cells.
    Brain Res. 1977 Jul 1;129(2):247-63 PMID: 560237
  71. Acidic and basic fibroblast growth factor mRNAs are increased in striatum following MPTP-induced dopamine neurofiber lesion: assay by quantitative PCR.
    Brain Res Mol Brain Res. 1993 Jun;18(4):275-84 PMID: 7686995
  72. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons.
    J Neurosci. 2000 May 1;20(9):3214-20 PMID: 10777786
  73. Prominent perikaryal expression of alpha- and beta-synuclein in neurons of dorsal root ganglion and in medullary neurons.
    Exp Neurol. 2001 Dec;172(2):354-62 PMID: 11716559
  74. Alpha-Synuclein is degraded by both autophagy and the proteasome.
    J Biol Chem. 2003 Jul 4;278(27):25009-13 PMID: 12719433
  75. Neurodegenerative disease: amyloid pores from pathogenic mutations.
    Nature. 2002 Jul 18;418(6895):291 PMID: 12124613
  76. Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress.
    FASEB J. 2003 Nov;17(14):2151-3 PMID: 12958153
  77. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.
    Science. 1997 Jun 27;276(5321):2045-7 PMID: 9197268
  78. alpha-Synuclein locus triplication causes Parkinson's disease.
    Science. 2003 Oct 31;302(5646):841 PMID: 14593171
  79. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease.
    Science. 2001 Jul 13;293(5528):263-9 PMID: 11431533
  80. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
    Nat Med. 1998 Nov;4(11):1318-20 PMID: 9809558
  81. Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model.
    Am J Pathol. 2001 Dec;159(6):2215-25 PMID: 11733371
  82. alpha-synuclein promotes mitochondrial deficit and oxidative stress.
    Am J Pathol. 2000 Aug;157(2):401-10 PMID: 10934145
  83. Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion.
    J Biol Chem. 2002 Dec 13;277(50):48984-92 PMID: 12351643
  84. Impairment of the ubiquitin-proteasome system by protein aggregation.
    Science. 2001 May 25;292(5521):1552-5 PMID: 11375494
  85. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system.
    Neuron. 1995 Feb;14(2):467-75 PMID: 7857654
  86. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein.
    Biochemistry. 2000 Sep 5;39(35):10619-26 PMID: 10978144
  87. Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins.
    Biochemistry. 1998 Apr 7;37(14):4901-9 PMID: 9538008
  88. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
    J Neurosci. 2002 Apr 1;22(7):2780-91 PMID: 11923443
  89. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration.
    J Neurosci. 2003 Apr 15;23(8):3095-9 PMID: 12716914
  90. Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation.
    Mov Disord. 2001 Nov;16(6):1007-13 PMID: 11748731
  91. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice.
    Neurobiol Aging. 2003 Mar-Apr;24(2):245-58 PMID: 12498958
  92. Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein.
    J Biol Chem. 2002 Feb 22;277(8):6344-52 PMID: 11744721
  93. alpha-Synuclein forms a complex with transcription factor Elk-1.
    J Neurochem. 2001 Apr;77(1):239-52 PMID: 11279280
  94. Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125.
    Biochem Biophys Res Commun. 2001 Feb 2;280(4):1085-92 PMID: 11162638
  95. Wild-type but not Parkinson's disease-related ala-53 --> Thr mutant alpha -synuclein protects neuronal cells from apoptotic stimuli.
    J Biol Chem. 2000 Aug 4;275(31):24065-9 PMID: 10818098
  96. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells.
    J Neurochem. 2001 Aug;78(4):899-908 PMID: 11520910
  97. NACP, a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation.
    Biochem Biophys Res Commun. 1997 Aug 28;237(3):611-6 PMID: 9299413
  98. Evidence that alpha-synuclein functions as a negative regulator of Ca(++)-dependent alpha-granule release from human platelets.
    Blood. 2002 Oct 1;100(7):2506-14 PMID: 12239163
  99. Alpha-synuclein and the Lewy body disorders.
    Curr Opin Neurol. 2001 Aug;14(4):423-32 PMID: 11470957
  100. Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line.
    J Biol Chem. 2002 Oct 11;277(41):38884-94 PMID: 12145295
  101. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia.
    Ann Neurol. 2004 Feb;55(2):164-73 PMID: 14755719
  102. Induction of neuronal death by alpha-synuclein.
    Eur J Neurosci. 2000 Aug;12(8):3073-7 PMID: 10971650
  103. Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment.
    Exp Neurol. 2002 Jul;176(1):98-104 PMID: 12093086
  104. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.
    J Neurochem. 2000 Feb;74(2):721-9 PMID: 10646524
  105. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.
    Neuron. 2002 May 16;34(4):521-33 PMID: 12062037
  106. Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells.
    Neurosci Lett. 2000 May 12;285(2):79-82 PMID: 10793231
  107. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats.
    Neuroreport. 2002 Aug 7;13(11):1437-41 PMID: 12167769
  108. alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases.
    J Biol Chem. 2001 Feb 9;276(6):3879-84 PMID: 11078745
  109. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro.
    Biochemistry. 2003 Jul 22;42(28):8530-40 PMID: 12859200
  110. Neuropathology of synuclein aggregates.
    J Neurosci Res. 2000 Jul 15;61(2):121-7 PMID: 10878583
  111. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10813-8 PMID: 12122208
  112. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.
    Proc Natl Acad Sci U S A. 1998 May 26;95(11):6469-73 PMID: 9600990
  113. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes.
    J Biol Chem. 1998 Apr 17;273(16):9443-9 PMID: 9545270
  114. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult.
    J Neurochem. 2001 Feb;76(4):998-1009 PMID: 11181819
  115. Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease.
    Ann Neurol. 2000 Feb;47(2):201-10 PMID: 10665491
  116. Synuclein-1 is selectively up-regulated in response to nerve growth factor treatment in PC12 cells.
    J Neurochem. 2001 Feb;76(4):1165-76 PMID: 11181836
  117. Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination.
    Mol Cell Neurosci. 2002 Oct;21(2):223-38 PMID: 12401444
  118. Transgenic models of alpha-synuclein pathology: past, present, and future.
    Ann N Y Acad Sci. 2003 Jun;991:171-88 PMID: 12846986
  119. Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid.
    Am J Pathol. 1999 Oct;155(4):1173-81 PMID: 10514400
  120. alpha-Synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells.
    J Biol Chem. 2002 Mar 29;277(13):11465-72 PMID: 11790792
  121. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded.
    Biochemistry. 1996 Oct 29;35(43):13709-15 PMID: 8901511
  122. Structural and functional implications of C-terminal regions of alpha-synuclein.
    Biochemistry. 2002 Nov 19;41(46):13782-90 PMID: 12427041
  123. Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein.
    J Neurochem. 2000 Dec;75(6):2546-54 PMID: 11080208
  124. Alpha-synuclein in Lewy bodies.
    Nature. 1997 Aug 28;388(6645):839-40 PMID: 9278044
  125. Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies.
    Hum Mol Genet. 2003 Oct 15;12(20):2625-35 PMID: 12928483
  126. Cocaine abusers have an overexpression of alpha-synuclein in dopamine neurons.
    J Neurosci. 2003 Apr 1;23(7):2564-71 PMID: 12684441
  127. Induction of alpha-synuclein aggregation by intracellular nitrative insult.
    J Neurosci. 2001 Oct 15;21(20):8053-61 PMID: 11588178
  128. Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation.
    FASEB J. 2002 Feb;16(2):210-2 PMID: 11744621
  129. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro.
    J Biol Chem. 1999 Mar 19;274(12):7619-22 PMID: 10075647
  130. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype.
    Ann Neurol. 1999 May;45(5):611-7 PMID: 10319883
  131. A Drosophila model of Parkinson's disease.
    Nature. 2000 Mar 23;404(6776):394-8 PMID: 10746727
  132. alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins.
    Proc Natl Acad Sci U S A. 2001 Jul 31;98 (16):9110-5 PMID: 11481478
  133. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.
    Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):571-6 PMID: 10639120
  134. Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development.
    J Neurochem. 1998 Jul;71(1):338-44 PMID: 9648883
  135. alpha-Synuclein is phosphorylated in synucleinopathy lesions.
    Nat Cell Biol. 2002 Feb;4(2):160-4 PMID: 11813001
  136. Neuropathology in mice expressing human alpha-synuclein.
    J Neurosci. 2000 Aug 15;20(16):6021-9 PMID: 10934251
  137. Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function.
    J Biol Chem. 2003 Apr 4;278(14):11753-9 PMID: 12551928
  138. Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrative stress.
    Brain Res. 2002 May 31;938(1-2):73-80 PMID: 12031537
  139. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity.
    Hum Mol Genet. 2000 Nov 1;9(18):2683-9 PMID: 11063727
  140. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures.
    J Neurochem. 2002 Apr;81(2):301-6 PMID: 12064477
  141. Synucleins are a novel class of substrates for G protein-coupled receptor kinases.
    J Biol Chem. 2000 Aug 25;275(34):26515-22 PMID: 10852916
  142. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein.
    J Mol Biol. 2002 Jan 25;315(4):799-807 PMID: 11812148
  143. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly.
    J Biol Chem. 2001 Jan 26;276(4):2380-6 PMID: 11060312
  144. Attenuation of dopamine transporter activity by alpha-synuclein.
    Neurosci Lett. 2003 Apr 17;340(3):189-92 PMID: 12672538
  145. Regulation of alpha-synuclein by bFGF in cultured ventral midbrain dopaminergic neurons.
    J Neurochem. 2003 Feb;84(4):803-13 PMID: 12562524
  146. Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins.
    J Biol Chem. 2001 Nov 9;276(45):41958-62 PMID: 11553616
  147. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation.
    Ann Neurol. 2001 Mar;49(3):313-9 PMID: 11261505
  148. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism.
    Biochemistry. 2002 Apr 9;41(14):4595-602 PMID: 11926821
  149. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility.
    Cell. 2002 Oct 18;111(2):209-18 PMID: 12408865
  150. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein.
    J Neurosci. 2002 Oct 15;22(20):8797-807 PMID: 12388586
  151. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
    Biochemistry. 2003 Apr 8;42(13):3696-700 PMID: 12667059
  152. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?
    Nat Cell Biol. 2000 Jul;2(7):E115-9 PMID: 10878819
  153. alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome.
    FEBS Lett. 2001 Nov 30;509(1):22-6 PMID: 11734199
  154. Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor?
    Neurology. 2000 Mar 14;54(5):1195-8 PMID: 10720300
  155. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function.
    J Biol Chem. 2003 Nov 7;278(45):44405-11 PMID: 12923179
  156. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies.
    J Clin Invest. 2002 Nov;110(10):1429-39 PMID: 12438441
  157. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions.
    Science. 2000 Nov 3;290(5493):985-9 PMID: 11062131
  158. Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons.
    Brain Res Dev Brain Res. 1997 Mar 17;99(1):87-94 PMID: 9088569
  159. Developmental expression of alpha-synuclein in rat hippocampus and cerebral cortex.
    Neuroscience. 1999;91(2):651-9 PMID: 10366022
  160. Pharmacological prevention of Parkinson disease in Drosophila.
    Nat Med. 2002 Nov;8(11):1185-6 PMID: 12411925
  161. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons.
    Neuroreport. 2000 Jan 17;11(1):211-3 PMID: 10683860
  162. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death.
    J Neurosci. 2001 Dec 15;21(24):9549-60 PMID: 11739566
  163. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons.
    Neuron. 2002 Dec 19;36(6):1007-19 PMID: 12495618
  164. Synucleins in synaptic plasticity and neurodegenerative disorders.
    J Neurosci Res. 1999 Oct 1;58(1):120-9 PMID: 10491577
  165. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice.
    J Neurochem. 2001 May;77(4):1181-4 PMID: 11359883
  166. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra.
    Hum Gene Ther. 2002 Mar 20;13(5):605-12 PMID: 11916484
  167. Reduced expression of the G209A alpha-synuclein allele in familial Parkinsonism.
    Ann Neurol. 1999 Sep;46(3):374-81 PMID: 10482268
  168. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro.
    J Neurochem. 2003 Aug;86(4):836-47 PMID: 12887682
  169. Regulation of connexin-43, GFAP, and FGF-2 is not accompanied by changes in astroglial coupling in MPTP-lesioned, FGF-2-treated parkinsonian mice.
    J Neurosci Res. 1996 Dec 1;46(5):606-17 PMID: 8951672
  170. Biochemical characterization of the core structure of alpha-synuclein filaments.
    J Biol Chem. 2002 May 24;277(21):19213-9 PMID: 11893734
  171. Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies.
    J Biol Chem. 2000 Jun 16;275(24):18344-9 PMID: 10747881
  172. Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.
    Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14524-9 PMID: 12376616
Article Info
Journal
Molecular neurobiology
Abbr.
Mol Neurobiol
ISSN
0893-7648
DOI
10.1385/MN:30:1:001
Published
2004-08-00
Pages
1-21
Language
English
Region
United States
NLM ID
8900963
Subset
IM
External Links
PubMed source DOI: 10.1385/MN:30:1:001 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2